natgillin/translations-raw huggingface dataset:
The usual dose is 5 million IU (3 to 9 million IU) administered subcutaneously three times a week (every other day). 
Običajni odmerek je 5 milijonov i.e. (3 do 9 milijonov i.e.), dan subkutano trikrat na teden (vsak drugi dan).
These symptoms have been reported more frequently when shosaikoto, a Chinese herbal medicine, is administered concomitantly with interferon alpha (see section 4.4). 
O teh simptomih so poročali pogosteje pri sočasni uporabi kitajskega zeliščnega pripravka shosaikoto in interferona alfa (glejte poglavje 4.4).
Patients who received IntronA plus ribavirin were less likely to respond than patients who received pegylated interferon alfa-2b and ribavirin. 
Pri bolnikih, ki so prejeli zdravilo IntronA z ribavirinom, je bila manjša verjetnost odziva kot pri tistih, ki so prejeli pegilirani interferon alfa-2b in ribavirin.
Hypertriglyceridemia and aggravation of hypertriglyceridemia, sometimes severe, have been observed. 
Opazili so hipertrigliceridemijo in poslabšanje hipertrigliceridemije, ki je bilo včasih hudo, zato priporočamo spremljanje lipidov v krvi.
Periodontal (affecting gums) and dental disorders, change in colour of the tongue, altered mental status, loss of consciousness, acute hypersensitivity reactions including urticaria (hives), angioedema (swelling of the hands, feet, ankles, face, lips, mouth, or throat which may cause difficulty in swallowing or breathing), bronchoconstriction and anaphylaxis (a severe, whole-body allergic reaction) have been reported, but their frequency is unknown. 
Poročali so tudi o paradontalni bolezni (prizadetost dlesni), zobnih boleznih, spremembi barve jezika, spremenjenem duševnem stanju, izgubi zavesti ter akutnih preobčutljivostnih reakcijah, vključno z urtikarijo (koprivnico), angioedemom (otekanjem dlani, stopal, gležnjev, obraza, ustnic, ust ali žrela, ki lahko povzroči težave pri požiranju ali dihanju), bronhokonstrikcijo in anafilaksijo (huda alergijska reakcija po vsem telesu), vendar njihova pogostnost ni znana.
Extreme care must be taken to avoid pregnancy in female patients or in partners of male patients taking IntronA in combination with ribavirin. 
Ribavirin lahko povzroči hude poškodbe ploda, če se uporablja med nosečnostjo, zato je potrebna skrajna previdnost v izogib nosečnosti pri bolnicah ali pri partnerkah bolnikov, ki jemljejo zdravilo IntronA v kombinaciji z ribavirinom.
Concomitant chemotherapy 
Sočasna kemoterapija
If thyroid abnormalities are detected, the patient's thyroid status should be evaluated and treated as clinically appropriate. 
Če ugotovite motnje delovanja ščitnice, je treba pri bolniku oceniti stanje žleze ščitnice in ga zdraviti glede na klinično stanje.
Myocardial infarction, cardiac ischaemia Congestive heart failure, pericardial effusion, arrhythmia 
palpitacije, tahikardija perikarditis kardiomiopatija miokardni infarkt, ishemija srca kongestivno srčno popuščanje, perikardni izliv, aritmija
IntronA was administered at a dose of 3 MIU 3 times a week as monotherapy or in combination with ribavirin. 
Zdravilo IntronA so dajali bolnikom v odmerku 3 mio i.e. trikrat na teden, v monoterapiji ali v kombinaciji z ribavirinom.
Maintenance therapy 
Vzdrževalna terapija
HCV/HIV Coinfection 
Sočasna okužba s HCV/HIV
Check with your doctor immediately if you have any of these symptoms. 
Če imate katerega od teh simptomov, se nemudoma posvetujte z zdravnikom.
Inject the solution by pushing the plunger all the way down gently. 
Raztopino injicirajte tako, da bat nežno potisnete do konca.
No studies have been conducted in juvenile animals to examine the effects of treatment with interferon alfa-2b on growth, development, sexual maturation, and behaviour. 
Študije za proučevanje učinkov zdravljenja z interferonom alfa-2b na rast, razvoj, spolno zorenje in vedenje živali niso bile opravljene pri mladih živalih.
Hyperkinesia, tremor, dysphonia, paresthaesia, hypoaesthesia, hyperaesthesia, concentration impaired, somnolence 
glavobol, omotica hiperkinezija, tremor, disfonija, parestezije, hipoestezija, hiperestezija, motnje koncentracije, zaspanost
Co-infected patients with advanced cirrhosis receiving HAART may be at increased risk of hepatic decompensation and death. 
Pri bolnikih, ki so sočasno okuženi z virusom HIV in imajo napredovano cirozo ter prejemajo terapijo HAART, je lahko povečano tveganje za jetrno dekompenzacijo in smrt.
While pyrexia may be associated with the flu-like syndrome reported commonly during interferon therapy, other causes of persistent pyrexia must be ruled out. 
Četudi je zvišana telesna temperatura lahko povezana z gripoznim sindromom, ki je pogost med zdravljenjem z interferonom, morate najprej izključiti druge vzroke za trdovratno zvišano telesno temperaturo.
Headache, dizziness 
zardevanje, bledica
HOW TO SELF INJECT INTRONA Syringe with an unattached needle 
KAKO SI LAHKO SAMI INJICIRATE ZDRAVILO INTRONA Brizga z nepritrjeno iglo
See section 4.4 Class label for interferon products, see below Pulmonary arterial hypertension. 
Velja za skupino zdravil, ki vsebujejo interferone - glejte Pljučna arterijska hipertenzija spodaj.
The administered dose should be reduced by 50 % in case of occurrence of haematological disorders (white blood cells < 1,500/mm 3, granulocytes < 1,000/mm 3, thrombocytes < 100,000/mm 3). 
Če se pojavijo hematološke motnje (število levkocitov < 1.500/mm 3, število granulocitov < 1.000/mm število trombocitov < 100.000/mm 3), odmerek zmanjšajte za 50 %.
Chronic myelogenous leukaemia The recommended dose of IntronA is 4 to 5 million IU/m2 administered daily subcutaneously. 
Kronična mieloična levkemija Priporočeni odmerek zdravila IntronA je 4 do 5 milijonov i.e./m2 dnevno in se injicira subkutano.
Treatment should be continued in patients who exhibit negative HCV-RNA. 
Pri tistih bolnikih, ki imajo negativen izvid HCV-RNA, nadaljujte z zdravljenjem.
Possible side effects listed below are grouped by frequency of occurrence: Very common (affects more than 1 user in 10) Common 
Spodaj navedeni možni neželeni učinki so razporejeni po pogostnosti pojavljanja: Zelo pogosti
Patients were randomized to receive either pegylated interferon alfa-2b (1.5 µg/kg/week) plus ribavirin (800 mg/day) or IntronA (3 MIU TIW) plus ribavirin (800 mg/day) for 48 weeks with a follow-up period of 6 months. 
Bolnike so naključno razporedili bodisi v skupino, ki je prejemala pegiliran interferon alfa-2b (v odmerku 1,5 µg/kg/teden) z ribavirinom (v odmerku 800 mg/dan), ali pa v skupino, ki je prejemala zdravilo IntronA (3 mio i.e. trikrat na teden) z ribavirinom (v odmerku 800 mg/dan), v obdobju 48 tednov, z nadaljnjim 6-mesečnim obdobjem spremljanja bolnikov.
Be sure the tip of needle is in the IntronA solution. 
Pazite, da bo konica igle potopljena v raztopino zdravila IntronA.
5 million IU/0.5 mL 
5 milijonov i.e./0,5 ml
Furthermore, suicidal ideation or attempts were reported more frequently compared to adult patients (2.4 % vs 1 %) during treatment and during the 6 month follow-up after treatment. 
Poleg tega so pri pediatričnih bolnikih med zdravljenjem in v 6-mesečnem obdobju spremljanja bolnikov po zdravljenju pogosteje poročali o samomorilnih mislih ali poskusih samomora kot pri odraslih bolnikih (2,4 % v primerjavi z 1 %).
Diarrhoea, vomiting, nausea, abdominal pain Mouth ulceration, stomatitis ulcerative, stomatitis, right upper quadrant pain, dyspepsia, glossitis, gastroesophageal reflux, rectal disorder, gastrointestinal disorder, constipation, loose stools, toothache, tooth disorder 
driska, bruhanje, navzea, trebušne bolečine razjede v ustih, ulcerozni stomatitis, stomatitis, bolečine v desnem zgornjem kvadrantu trebuha, dispepsija, glositis, gastroezofagealni refluks, bolezni rektuma, bolezen prebavil, zaprtje, vodeno blato, zobobol, bolezni zob
Treatment of adult patients with Philadelphia chromosome or bcr/abl translocation positive chronic myelogenous leukaemia. 
Zdravljenje odraslih bolnikov s kronično mieloično levkemijo s prisotnim kromosomom Philadelphia ali translokacijo gena bcr/abl.
Remove the cap from the vial. 
Z viale snemite zaščitno kapico.
Pack of 2 vials 
2 viali
Children 3 years of age and older and adolescents IntronA is indicated, in a combination regimen with ribavirin, for the treatment of children 3 years of age and older and adolescents, who have chronic hepatitis C, not previously treated, without liver decompensation, and who are positive for HCV-RNA. 
Zdravilo IntronA je indicirano v kombinaciji z ribavirinom za zdravljenje otrok, starih 3 leta ali več, in mladostnikov, ki imajo predhodno nezdravljen kronični hepatitis C brez jetrne dekompenzacije in pozitiven izvid HCV-RNA.
If unable to activate, discard immediately into an approved sharps collector. 
Če pripomočka za zaščito igle ne morete aktivirati, brizgo z iglo takoj zavrzite v primeren zbiralnik za ostre predmete.
Each vial contains 10 million IU in 1 mL of solution. 
Ena viala vsebuje 10 milijonov i.e. v 1 ml raztopine.
Table 7 Mean (% CV) multiple-dose pharmacokinetic parameters for IntronA and ribavirin capsules when administered to children or adolescents with chronic hepatitis C 
Preglednica 7 Srednja vrednost (% CV) farmakokinetičnih parametrov pri večkratnem odmerjanju zdravila IntronA in kapsul ribavirina pri otrocih ali mladostnikih s kroničnim hepatitisom C
Any unused medicinal product must be discarded after withdrawal of the dose and in accordance with local requirements. 
Neuporabljeno zdravilo ali odpadni material zavrzite skladno z lokalnimi predpisi.
The best way to use IntronA in this indication is in combination with ribavirin. 
Pri tej indikaciji je zdravilo IntronA najbolje uporabljati v kombinaciji z ribavirinom.
Pulmonary infiltrates, pneumonitis, and pneumonia, occasionally resulting in fatality, have been observed rarely in interferon alpha treated patients, including those treated with IntronA. 
Pri bolnikih, zdravljenih z interferonom alfa, vključno s tistimi, zdravljenimi z zdravilom IntronA, so redko opažali pljučne infiltrate, pnevmonitis in pljučnico, ki so se občasno končali celo s smrtnim izidom.
Not known side effects: 
Neželeni učinki z neznano pogostnostjo:
Patients who also have HIV infection: Lactic acidosis and worsening liver function are side effects associated with Highly Active Anti-Retroviral Therapy (HAART), an HIV treatment. 
Bolniki, okuženi s HIV: Neželena učinka, povezana z visoko aktivnim protiretrovirusnim zdravljenjem (HAART, vrsta zdravljenja okužbe s HIV), sta laktoacidoza in slabšanje delovanja jeter.
Commonly reported side effects: thirst, dehydration, high blood pressure, migraines, swollen glands, flushing, menstrual problems, decreased sexual drive, vaginal problem, breast pain, pain in testicle, problems with thyroid gland, red gums, dry mouth, red or sore mouth or tongue, tooth ache or tooth disorder, herpes simplex (fever blisters), taste change, upset stomach, dyspepsia (heartburn), constipation, enlargement of liver (liver problems, sometimes severe), loose stools, bedwetting in children, inflammation of the sinuses, bronchitis, eye pain, problem with your tear ducts, conjunctivitis (“pink eye”), agitation, sleepiness, sleepwalking, problem with behaviour, nervousness, stuffy or runny nose, sneezing, rapid breathing, pale or reddened skin, bruising, problem with skin or nails, psoriasis (new or worsened), increased sweating, increased need to pass urine, fine shaking movements, decreased sensitivity to touch, arthritis. 
Pogosto poročani neželeni učinki: žeja, dehidracija, zvišan krvni tlak, migrene, otekle bezgavke, zardevanje, težave z menstruacijo, zmanjšana spolna sla, vaginalne težave, bolečine v dojkah, bolečine v modih, težave z žlezo ščitnico, pordele dlesni, suha usta, pordela ali vneta usta ali jezik, zobobol ali zobne bolezni, herpes simpleks (vročinske razjede), sprememba okusa, želodčne težave, dispepsija (zgaga), zaprtje, povečanje jeter (jetrne težave, včasih hude), vodeno blato, močenje postelje pri otrocih, vnetje sinusov, bronhitis, očesne bolečine, težave s solznimi kanalčki, konjunktivitis (“rdeče oko”), vznemirjenost, zaspanost, hoja v spanju, vedenjske težave, živčnost, zamašen nos ali izcedek iz nosu, kihanje, hitro dihanje, bleda ali pordela koža, podplutbe, težave s kožo ali nohti, luskavica (novonastala ali poslabšanje obstoječe), povečano potenje, večja potreba po odvajanju urina, drobni tresoči gibi, zmanjšana občutljivost za dotik, artritis.
IntronA is available in twelve different pack sizes: 
Zdravilo IntronA je na voljo v dvanajstih različnih pakiranjih: 1 viala,
- The other ingredients are disodium phosphate anhydrous, sodium dihydrogen phosphate monohydrate, edetate disodium, sodium chloride, m-cresol, polysorbate 80 and water for injections. 
- Pomožne snovi so brezvodni natrijev hidrogenfosfat, natrijev dihidrogen fosfat monohidrat, dinatrijev edetat, natrijev klorid, meta-krezol, polisorbat 80 in voda za injekcije.
One dose of IntronA is given on each scheduled day. 
Vsak načrtovani dan dajte en odmerek zdravila IntronA.
Excipients: disodium phosphate anhydrous, sodium dihydrogen phosphate monohydrate, edetate disodium, sodium chloride, m-cresol, polysorbate 80 and water for injections. 
Pomožne snovi: brezvodni natrijev hidrogenfosfat, natrijev dihidrogen fosfat monohidrat, dinatrijev edetat, natrijev klorid, meta-krezol, polisorbat 80 in voda za injekcije.
Clean the rubber stopper on the top of the vial containing the IntronA solution with a cleansing swab. 
S čistilnim tamponom očistite gumijasti zamašek na vrhu viale z raztopino zdravila IntronA.
Severe CNS effects, particularly depression, suicidal ideation and attempted suicide have been observed in some patients during IntronA therapy, and even after treatment discontinuation mainly during the 6-month follow-up period. 
Psihiatrične motnje in centralni živčni sistem (CŽS) Med terapijo z zdravilom IntronA in celo po ukinitvi zdravljenja, predvsem v 6-mesečnem obdobju spremljanja, so pri nekaterih bolnikih opažali hude učinke na CŽS, še posebej depresijo, samomorilne misli in poskus samomora.
Chronic Myelogenous Leukaemia: 4-5 million IU/m 2 daily injected subcutaneously (under the skin). 
Kronična mieloična levkemija: 4 do 5 milijonov i.e./m 2 na dan s subkutano (podkožno) injekcijo.
Very commonly reported side effects: pain, swelling and redness or skin damage at site of injection, hair loss, dizziness, changes in appetite, stomach or abdominal pains, diarrhoea, nausea (feeling sick), viral infection, depression, emotional lability, insomnia, anxiety, sore throat and painful swallowing, fatigue, chills/rigors, fever, flu-like reaction, feeling of general discomfort, headaches, weight loss, vomiting, irritability, weakness, mood swings, coughing (sometimes severe), shortness of breath, itching, dry skin, rash, sudden and severe muscle pain, joint pain, musculoskeletal pain, changes in laboratory blood values including decreased white blood cell count. 
Zelo pogosto poročani neželeni učinki: bolečina, otekanje in pordelost ali poškodbe kože na mestu injiciranja, izpadanje las, omotica, sprememba apetita, želodčne ali trebušne bolečine, driska, slabost (siljenje na bruhanje), virusna okužba, depresija, čustvena nestabilnost, nespečnost, tesnoba, vnetje žrela in bolečine pri požiranju, utrujenost, mrzlica/tresavica, zvišana telesna temperatura, gripi podobna reakcija, občutek splošnega neugodja, glavoboli, hujšanje, bruhanje, razdražljivost, šibkost, nihanje razpoloženja, kašelj (včasih hud), kratka sapa, srbenje, suha koža, izpuščaj, nenadne in hude mišične bolečine, sklepne bolečine, mišičnoskeletne bolečine, spremembe izvidov laboratorijskih krvnih preiskav vključno z zmanjšanim številom belih krvnih celic.
You must use an effective contraceptive during the time you are taking ribavirin and for 4 months after stopping treatment. 
V času jemanja ribavirina in še 4 mesece po zaključku zdravljenja morate uporabljati učinkovito kontracepcijo.
18 million IU/3 mL solution for injection or infusion 1 multiple dose vial 
18 milijonov i.e./3 ml raztopina za injiciranje ali infundiranje 1 viala z večkratnimi odmerki
Patients were randomized to receive either pegylated interferon alfa-2b (100 or 150 µg /week based on weight) plus ribavirin (800-1,200 mg/day based on weight) or IntronA (3 MIU TIW) plus ribavirin (800-1,200 mg/day based on weight). 
Bolnike so naključno razporedili bodisi v skupino, ki je prejemala pegiliran interferon alfa-2b (v odmerkih 100 ali 150 µg/teden, odvisno od telesne mase) z ribavirinom (v odmerku 800-1.200 mg/dan, odvisno od telesne mase), ali pa v skupino, ki je prejemala zdravilo IntronA (3 m.i.e.
As induction therapy, interferon alfa-2b is administered intravenously at a dose of 20 million IU/m daily for five days a week for a four-week period; the calculated interferon alfa-2b dose is added to sodium chloride 9 mg/mL (0.9 %) solution for injection and administered as a 20-minute infusion (see section 6.6). 
Izračunani odmerek interferona alfa-2b dodajte natrijevemu kloridu 9 mg/ml (0,9 %) raztopini za injekcije in ga dajte bolniku v 20-minutni infuziji (glejte poglavje 6.6).
Photosensitivity reaction, maculopapular rash, eczema, acne, skin disorder, nail disorder, skin discolouration, pruritus, dry skin, erythema, bruise, sweating increased 
alopecija, izpuščaj fotosenzitivne reakcije, makulopapulozni izpuščaj, ekcem, akne, kožne bolezni, bolezni nohtov, obarvanje kože, pruritus, suha koža, eritem, modrice, povečano potenje
IntronA therapy may be initiated if TSH levels can be maintained in the normal range by medication. 
Terapijo z zdravilom IntronA lahko začnete, če je koncentracijo TSH mogoče z zdravili ohranjati v normalnem razponu vrednosti.
Pack of 12 vials, 72 injection syringes with attached needle of 1 mL and 144 cleansing swabs Not all pack sizes may be marketed. 
12 vial, 72 (1-mililitrskih) injekcijskih brizg s pritrjeno iglo in 144 čistilnih tamponov Na trgu morda ni vseh navedenih pakiranj.
Corresponding dose (million IU) using IntronA 25 million IU/2.5 mL solution for injection or infusion 
Ustrezen odmerek (milijoni i.e.) uporabljenega zdravila IntronA 25 milijonov i.e./2,5 ml raztopina za injiciranje ali infundiranje
Results from the clinical trial conducted with pegylated interferon alfa-2b and ribavirin In a multicentre trial children and adolescents 3 to 17 years of age with compensated chronic hepatitis C and detectable HCV-RNA were treated with peginterferon alfa-2b 60 g/m2 plus ribavirin 
Izsledki kliničnega preskušanja, opravljenega s pegiliranim interferonom alfa-2b in ribavirinom Otroke in mladostnike, stare od 3 do 17 let, s kompenziranim kroničnim hepatitisom C in merljivimi vrednostmi HCV-RNA so vključili v multicentrično preskušanje in jih zdravili s peginterferonom alfa2b v odmerku 60 g/m2 in ribavirinom v odmerku 15 mg/kg na dan enkrat na teden v obdobju 24 ali 48 tednov, glede na genotip HCV in virusno breme na začetku preskušanja.
Corresponding dose (million IU) using IntronA 18 million IU/3 mL solution for injection or infusion 
Ustrezen odmerek (milijoni i.e.) uporabljenega zdravila IntronA 18 milijonov i.e./3 ml raztopina za injiciranje ali infundiranje
In the presence of thyroid dysfunction, IntronA treatment may be continued if TSH levels can be maintained in the normal range by medication. 
V primeru motenj delovanja žleze ščitnice lahko terapijo z zdravilom IntronA nadaljujete, če boste z zdravili lahko ohranjali koncentracijo TSH v normalnem razponu vrednosti.
Follicular lymphoma: Adjunctively with chemotherapy, 5 million IU 3 times a week (every other day) injected subcutaneously (under the skin). 
Folikularni limfom: dodatno ob kemoterapiji, 5 milijonov i.e. 3-krat na teden (vsak drugi dan) s subkutano (podkožno) injekcijo.
IntronA 5 MIU 
IntronA 5 mio i.e.
Treatment should be continued for another 6-month period (i.e., a total of 12 months) in patients who exhibit negative HCV-RNA at month 6, and with viral genotype 1 (as determined in a pre-treatment sample) and high pre-treatment viral load. 
Pri bolnikih z negativnim izvidom HCV-RNA po 6 mesecih, virusnim genotipom 1 (določenim v vzorcu, odvzetem pred terapijo) ter veliko virusno obremenitvijo pred začetkom zdravljenja zdravljenje podaljšajte še za 6 mesecev (t.j.
IntronA 18 million IU/3 mL solution for injection or infusion 
IntronA 18 milijonov i.e./3 ml raztopina za injiciranje ali infundiranje
If treatment with alpha interferon is judged necessary in these patients, the presence of psychiatric co-morbidities and the potential for other substance use should be carefully assessed and adequately managed before initiating therapy. 
Če ocenite, da je pri takšnih bolnikih zdravljenje z interferonom alfa potrebno, morate pri njih skrbno preveriti, ali imajo morda kakšno sočasno psihiatrično motnjo in če obstaja možnost uživanja opojnih substanc.
Check with your doctor if you think you are getting an infection. 
Če mislite, da ste se okužili, se posvetujte z zdravnikom.
Co-administration of IntronA with ribavirin increased the efficacy of IntronA by at least two fold for the treatment of chronic hepatitis C in naïve patients. 
Sočasna uporaba zdravila IntronA z ribavirinom za zdravljenje kroničnega hepatitisa C pri predhodno nezdravljenih bolnikih je povečala učinkovitost zdravila IntronA za najmanj dvakrat.
IntronA treatment may be initiated if TSH levels can be maintained in the normal range by medication. 
Zdravljenje z zdravilom IntronA lahko uvedete, če boste vrednosti TSH lahko z zdravili ohranjali v normalnem razponu.
In addition, dry mouth could have a damaging effect on teeth and mucous membranes of the mouth during long-term treatment with the combination of IntronA and ribavirin. 
Poleg tega bi lahko med dolgotrajnim zdravljenjem s kombinacijo zdravila IntronA in ribavirina imela škodljiv vpliv na zobe in ustno sluznico tudi suha usta.
IntronA is administered subcutaneously at a dose of 3 million IU three times a week (every other day) to adult patients, whether administered as monotherapy or in combination with ribavirin. 
Pri odraslih bolnikih se zdravilo IntronA uporablja subkutano v odmerku 3 milijone i.e. trikrat na teden (vsak drugi dan) ne glede na to, ali se zdravilo uporablja v monoterapiji ali v kombinirani terapiji z ribavirinom.
Check with your doctor immediately if any of the following side effects occur: - chest pain or persistent and severe cough; irregular or rapid heartbeat; shortness of breath, confusion, difficulty remaining alert, numbness or tingling sensation or pain in hands or feet; seizure (convulsions); trouble sleeping, thinking or concentrating; altered mental state; suicidal thoughts, suicide attempt, changed behaviour or aggressive behaviour (sometimes directed against others), hallucinations; severe stomach pain; black or tar like stools; blood in stool or urine, severe nosebleed; waxy pallor, high sugar level in blood, fever or chills beginning after a few weeks of treatment, lower back or side pain, difficult urination, problems with your eyes or your eyesight or hearing, loss of hearing, severe or painful reddening or sores on your skin or mucous membrane. 
• bolečina v prsih ali trdovraten in hud kašelj; neredno ali hitro bitje srca; kratka sapa, zmedenost, težava ostati buden, odrevenelost ali mravljinčenje ali bolečina v dlaneh ali stopalih; epileptični napadi (konvulzije); težave s spanjem, razmišljanjem ali zbranostjo; spremenjeno duševno stanje; samomorilne misli, poskus samomora, spremenjeno obnašanje ali agresivno obnašanje (včasih usmerjeno proti drugim), halucinacije; hude želodčne bolečine; črno ali smolnato blato; kri v blatu ali urinu, huda krvavitev iz nosu; voskasta bledica, visoka raven sladkorja v krvi, zvišana telesna temperatura ali mrzlica, ki nastopi po nekaj tednih zdravljenja, bolečina v spodnjem delu hrbta ali ob strani, težave z uriniranjem, težave z očmi ali vidom ali sluhom, izguba sluha, huda ali boleča pordelost ali ranice na koži ali sluznicah.
3 million IU/0.5 mL 
3 milijoni i.e./0,5 ml
Pack of 12 vials 
12 vial
One vial contains 18 million IU of interferon alfa-2b in 3 mL of solution. 
Ena viala vsebuje 18 milijonov i.e. interferona alfa-2b v 3 ml raztopine.
Very rarely: Not known: 
Zelo redki: Neznana pogostnost:
Use IntronA exactly as prescribed by your doctor. 
Pri uporabi zdravila IntronA natančno upoštevajte zdravnikova navodila.